-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$5.25275% Upside
Context Therapeutics Inc. Frequently Asked Questions
-
What analysts cover Context Therapeutics Inc.?
Context Therapeutics Inc. has been rated by research analysts at H.C. Wainwright, Piper Sandler in the past 90 days.